Client News

Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange

CARBIOS Announces Half-Year 2024 Financial results and Presents its Industrial and Commercial Progress

Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Formycon and Fresenius Kabi Receive FDA Approval for FYB202/ OtulfiTM (ustekinumab-aauz)

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update

FDA Grants Approval for Stelara®1 Biosimilar FYB202/OtulfiTM2 (ustekinumab-aauz)

Formycon and Fresenius Kabi Receive European Commission Approval for FYB202/Otulfi® (ustekinumab) for the Treatment of Serious Inflammatory Diseases

Affluent Medical – H1 2024 RESULTS: Major Advances in All Three Programs, Several Strategic Agreements Signed, Extension of Financial Runway to July 2025

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024